Resonant Therapeutics Company

Resonant Therapeutics’s platform allows for the simultaneous discovery of novel targets and high affinity, functional antibodies with unprecedented speed. Using novel insights into the tumor microenvironment and the immune system, their platform identifies targets and therapeutic candidates for any patient derived tumor tissue or cell line, including cancer stem cells. The platform is extensible to other microenvironment regulated disease. They have created a pipeline of candidates with potent, direct anti-tumor activity, initially in breast and ovarian cancers. Their antibodies are expected to work as a monotherapy or in synergistic combination with emerging immunotherapies.

Investors

Technology: Biotechnology, Pharmaceutical, Physical Security, Therapeutics
Industry: Early Drug Development
Headquarters: Santa Barbara, California, United States
Founded Date: 2014-01-01
Employees Number: 1-10
Investors Number: 1
Total Funding: 4490883
Estimated Revenue: Less than $1M
Last Funding Date: 2021-10-28
Last Funding Type: Venture - Series Unknown

Visit Website
info@resonantrx.com
Register and Claim Ownership